REMARKS

The undersigned attorney wishes to thank the Examiner for the courtesies extended during the Interview. During the Interview, the Examiner agreed that the amendments to claims set forth above, in addition to filing a terminal disclaimer to overcome the provisional double patenting rejection, will place the application in condition for allowance.

Claims 12-15 have been amended to replace the "gene" with the term --polynucleotide--. Support for this amendment is found in the specification at, for example, page 3, ¶¶ [0016]-[0017] and page 10, ¶¶ [0041]-[0043].

Claims 12 and 13 have further been amended to replace the term "comprises" with --consists essentially of--. Support for this amendment is found in the specification at, for example, page 10, ¶¶ [0041]-[0043].

It is submitted that no new matter has been introduced by the foregoing amendments. Approval and entry of the amendments is respectfully solicited.

§112, First Paragraph Written Description Rejection

Claims 12-15 were rejected under 35 USC §112, first paragraph. (Paper No. 04252004 at 2). In making the rejection, the Examiner asserted that the "partial sequences/fragments of SEQ ID NO: 2 is [sic] claimed with open language and the genus encompasses a variety of species with widely varying attributes," thus the Examiner reasoned that "the specification is insufficient to put one of skill in the art in possession of the features of all species within the claimed genus." (Id. at 3).

Application No.: 10/053,192

Amendment Dated: August 3, 2004

Reply to Office Action Dated: May 4, 2004

With a view towards furthering prosecution, and as suggested by the

Examiner during the Interview, claims 12 and 13 have been amended as set forth

above. Accordingly, it is respectfully submitted that the rejection is rendered moot and

should be withdrawn.

Provisional Obviousness-Type Double Patenting Rejection

Claims 6-7, 10-15, 19-27, 31, 32 and 37 were provisionally rejected under

the judicially created doctrine of obviousness-type double patenting as being

unpatentable over claims 6-15, 19-32 and 34-36 of copending parent Application Serial

No. 09/504,393. (Paper No. 04252004 at 4).

In making the rejection, the Examiner asserted that "[a]lthough the

conflicting claims are not identical, they are not patentable distinct from each other

because they are drawn to identical nucleic acid sequences encoding the same protein.

identical primers/probes, identical kits comprising said primer/probe, identical methods

of using said nucleic acid sequence and vectors and host cells comprising said nucleic

acid sequence." (Id.)

With a view towards furthering prosecution, submitted concurrently

herewith and expressly contingent upon the issuance of the '393 application is a

terminal disclaimer disclaiming the terminal part of any patent granted on the present

application that would extend beyond the expiration of the patent granted on the '393

10

1172646.2

Application No.: 10/053,192

Amendment Dated: August 3, 2004

Reply to Office Action Dated: May 4, 2004

application.^{1/} Accordingly, it is respectfully submitted that the provisional rejection is rendered moot and should be withdrawn.

Accordingly, for the reasons set forth above, entry of the amendments, withdrawal of all rejections, and allowance of all claims are respectfully requested. If the Examiner has any questions regarding this paper, please contact the undersigned.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Box Amendment, Commissioner for Patents, P.O. Box. 1450 Alexandria, VA 22313-1450, on August 3, 2004.

Gonzalo Merino, Ph.D., Reg. No. 51,192

Respectfully submitted,

By: Gonzalo Merino, Ph.D.

Reg. No. 51,192 BRYAN CAVE LLP

1290 Avenue of the Americas New York, NY 10104-3300

Phone: (212) 541-2000 Fax: (212) 541-4630

As a courtesy, a copy of the terminal disclaimer as filed is attached hereto as Exhibit A.